Name: 글로벌 시장 동향
SKU: PH7345
Availability: InStock

보고서 요약(국문)

개요
전 세계 비만세포증 치료 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
비만세포증은 유전성 면역 질환으로, 비만세포라고 불리는 특정 면역 세포가 피부, 뼈, 장 및 기타 장기에 축적되는 질환입니다. 이러한 비만세포의 비정상적인 증식은 피부의 가려운 발진, 설사와 같은 위장 문제, 뼈 통증 등 다양한 증상을 유발합니다. 특정 환경적 요인에 노출될 경우 아나필락시스(심각한 알레르기 반응)의 위험이 증가할 수 있습니다. 일부 경우, 비만세포증은 공격적으로 진행되어 치료하지 않으면 사망에 이를 수 있습니다. 비만세포증은 전염성이 없습니다.
비만세포증에는 피부형과 전신형의 두 가지 유형이 있습니다. 기본적으로 비만세포증은 완치할 수 없지만, 치료를 통해 증상을 관리하고 최소화할 수 있습니다. 항히스타민제, 류코트리엔 조절제, 비만세포 안정제, 코르티코스테로이드 크림은 가려운 피부 병변과 같은 알레르기 반응 증상을 완화할 수 있습니다. 아나필락시스 쇼크의 경우 에피네프린 주사가 일반적으로 사용됩니다. 클라드리빈과 같은 항암화학요법은 공격적인 전신성 비만세포증을 치료하는 데 사용됩니다. 공격적인 전신성 비만세포증 환자 중 일부는 동종 조혈모세포 이식(골수 이식이라고도 함)을 받을 수 있습니다.
시장 동향: 성장 요인
신약 치료제 도입 증가
신약 치료제의 도입이 증가함에 따라 예측 기간 동안 시장이 성장할 것으로 예상됩니다. 비만세포증은 완치할 수 없기 때문에 치료는 증상을 최소화하는 데 도움이 됩니다. 신약 치료제의 개발 및 도입은 비만세포증 관리와 관련된 미충족 의료 수요를 해결하고, 환자에게 더 나은 치료 결과를 제공하는 것을 목표로 합니다.

예를 들어, 2023년 1월 23일, 블루프린트 메디신즈 코퍼레이션(Blueprint Medicines Corporation)은 미국 식품의약국(FDA)으로부터 양성 전신 비만세포증(SM) 성인 환자 치료를 위한 AYVAKIT(아바프리티닙)의 보충 신약 허가 신청(supplemental new drug application) 승인을 받았습니다.
또한, 비만세포증 치료에 더 나은 결과를 보이는 새로운 치료제 개발을 위한 많은 임상 시험이 진행 중입니다. 이러한 규제 승인은 환자들이 새로운 치료제의 개발 및 도입에 대한 신뢰를 높이는 데 기여하고 있습니다.
예를 들어, 2023년 9월 11일, 환자 중심의 바이오제약 회사인 호스 테라퓨틱스(Hoth Therapeutics, Inc.)는 진행성 전신 비만세포증(AdvSM) 치료를 위한 새로운 분자 물질인 HT-KIT의 신약 개발 프로그램에 대해 논의하기 위해 미국 식품의약국(FDA)에 임상시험계획승인신청(IND) 전 회의를 개최했습니다. HT-KIT는 mRNA 프레임시프트를 유도하여 원종양유전자 cKIT를 표적으로 하는 안티센스 올리고뉴클레오티드로, 이미 FDA로부터 희귀의약품 지정을 받았습니다.
또한, 지속적인 연구 개발 노력으로 새로운 치료제가 발견되고 혁신적인 약물이 개발되고 있습니다. 분자 및 세포 수준에서 비만세포증에 대한 이해가 향상됨에 따라, 표적 작용 기전을 가진 새로운 치료제가 발굴 및 개발될 수 있습니다.
더 나아가, 비만세포증의 유병률 증가, FDA 승인 증가, 임상 시험 증가, 비만세포증 및 이용 가능한 치료법에 대한 인식 제고, 그리고 신약 및 첨단 치료법 개발의 진전은 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.

제한 요인
비만세포증 치료에 사용되는 다양한 약물과 관련된 합병증, 국소 코르티코스테로이드와 관련된 부작용, 비만세포증 치료의 높은 비용, 승인된 치료법의 제한, 그리고 적절한 치료법의 부족과 같은 요인들은 시장 성장을 저해할 것으로 예상됩니다.

시장 세분화 분석
전 세계 비만세포증 치료 시장은 질병 유형, 치료 유형, 판매 채널 및 지역별로 세분화됩니다.
비만세포 안정제 부문은 비만세포증 치료 시장 점유율의 약 45.2%를 차지했습니다.
비만세포 안정제 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 일반적으로 비만세포증은 완치할 수 없지만, 다양한 약물, 치료법 및 여러 가지 치료 옵션을 사용하여 증상을 최소화합니다. 비만세포 안정제는 비만세포증 치료에 가장 일반적으로 사용되는 약물입니다. 크로몰린 나트륨과 케토티펜과 같은 비만세포 안정제가 가장 많이 사용됩니다.
예를 들어, 제약 회사인 리테도스(Ritedose)는 2022년 1월 5일에 새로운 1회용 제네릭 제품인 크로몰린 나트륨 경구용액 100mg/5ml를 출시했습니다. 이 경구용액은 기존에 제네릭 흡입제 포트폴리오를 제공해 온 리테도스 제약(Ritedose Pharmaceuticals)의 새로운 제품 라인의 첫 번째 제품입니다. 크로몰린 나트륨은 비만세포 안정제로, 주로 비만세포증 증상 치료에 사용됩니다.
비만세포증에서는 비만세포가 과민해져 히스타민, 프로스타글란딘, 류코트리엔과 같은 매개체를 과다하게 분비합니다. 크로몰린 나트륨과 네도크로밀과 같은 비만세포 안정제는 비만세포 막을 안정화시켜 이러한 염증성 물질의 분비를 억제합니다.
비만세포 활성화는 가려움증, 홍조, 복통, 심한 경우 아나필락시스와 같은 다양한 증상을 유발합니다. 비만세포 안정제는 비만세포 매개체의 분비를 억제하여 이러한 증상의 강도와 빈도를 줄여 비만세포증 환자의 삶의 질을 향상시키며, 이러한 안정제의 광범위한 사용은 수요 증가로 이어집니다.

비만세포 안정제는 비만세포 매개체의 분비를 억제함으로써 이러한 증상의 강도와 빈도를 줄여줍니다. 지리적 분석
북미 지역은 시장 점유율의 약 39.1%를 차지했습니다.
북미 지역은 주요 기업들의 강력한 입지와 선진 의료 시설 덕분에 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 특히 미국은 비만세포증 치료 제품을 개발하는 제약 회사 및 의료 기기 회사와 같은 주요 기업들의 강력한 존재로 잘 알려져 있습니다. 이들 주요 기업들은 비만세포증 치료를 위한 새롭고 진보된 치료법을 개발하기 위해 임상 시험 및 연구 활동에 적극적으로 참여하고 있습니다.
또한, 이 지역은 병원, 전문 클리닉, 연구 및 학술 센터 등과 같은 선진 의료 인프라를 갖추고 있어 비만세포증 환자들에게 첨단 치료법을 활용한 더 나은 치료 결과를 제공하는 의료 시설을 제공합니다. 이 지역의 선진 의료 시설은 최소한의 위험으로 질환을 조기에 예방하는 데 도움이 됩니다.

경쟁 환경
전 세계 비만세포증 치료제 시장의 주요 업체로는 Novartis AG, Mylan N.V., Apotex Inc., Blueprint Medicines Corporation, CStone Pharmaceuticals, Viatris Inc., Cigna HealthCare, Ralington Pharma, Enzo Life Sciences, Inc., Genentech USA, Inc. 등이 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 비만세포증 치료제 시장에 상당한 영향을 미쳤습니다. 팬데믹으로 인해 임상시험의 시작과 진행에 차질이 생겼습니다. 비만세포증에 대한 새로운 치료법 개발을 포함한 연구 활동은 COVID-19 팬데믹에 대한 관심이 집중되면서 일시적으로 중단되었습니다. 또한 팬데믹은 전 세계적으로 이러한 치료제의 공급망에 차질을 초래했습니다.

시장 세분화
질병 유형별
• 피부 비만세포증
o 반점구진성 피부 비만세포증(색소성 두드러기)
o 미만성 피부 비만세포증
o 피부 비만세포종(단일 비만세포종)
o 지속성 반점성 모세혈관확장증
• 전신 비만세포증
o 양성 전신 비만세포증
o 잠복성 전신 비만세포증
o 다른 혈액 또는 골수 질환을 동반한 전신 비만세포증
o 공격성 전신 비만세포증
o 비만세포 백혈병
치료 유형별
• 항히스타민제
o H1 항히스타민제
o H2 항히스타민제
• 류코트리엔 조절제
• 비만세포 안정제
o 크로몰린 나트륨
o 케토티펜
• 국소 코르티코스테로이드
• 경구 스테로이드
• 비스포스포네이트
• 주사형 에피네프린
• 항암화학요법
o 클라드리빈
o 이마티닙
o 기타
• 동종 조혈모세포 이식(골수 이식)
• 골다공증 치료
• 기타
판매 채널별
• 유통 채널
o 병원 약국
o 소매 약국
o 온라인 약국
• 최종 사용자
o 병원
o 전문 클리닉
o 피부과 클리닉
o 연구 및 학술 센터
o 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
보고서를 구매해야 하는 이유

• 질병 유형, 치료 유형, 판매 채널 및 지역별 글로벌 비만세포증 치료 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.
• 모든 세그먼트를 포함한 비만세포증 치료 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 비만세포증 치료 시장 보고서는 약 61개의 표, 63개의 그림, 186페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global mastocytosis treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Mastocytosis is a genetic immune disorder, in which certain immune cells, called mast cells, build up under the skin and in the bones, intestines and other organs. This abnormal growth of mast cells causes a range of symptoms, including itchy bumps on the skin, gastrointestinal (GI) issues such as diarrhea, and bone pain. It can increase the risk of anaphylaxis (a severe allergic response) when patients come across certain environmental triggers. In some cases, the mastocytosis can be aggressive and lead to death if left untreated. Mastocytosis is not contagious.
There are two types of mastocytosis, cutaneous and systemic types. Basically, there is no cure for mastocytosis, but treatment can help to manage and minimize the symptoms. Antihistamines, leukotriene modifiers, mast cell stabilizers and corticosteroid creams can relieve the symptoms of an allergic reaction, such as itchy skin lesions. In case of anaphylactic shock, an epinephrine injection is commonly used. Chemotherapy such as cladribine is used to treat aggressive systemic mastocytosis. Some patients with aggressive systemic mastocytosis may undergo an allogeneic hematopoietic stem cell transplant (also called a bone marrow transplant).
Market Dynamics: Drivers
Increasing adoption of novel therapeutics
The increasing adoption of novel therapeutics is expected to drive the market over the forecast period. As there is no cure for mastocytosis, the treatment helps to minimize the symptoms. The development and adoption of novel therapeutics aim to address the unmet medical needs associated with the management of mastocytosis by providing more advanced approved therapeutics for better patient outcomes.
For instance, on January 23, 2023, Blueprint Medicines Corporation cleared the U.S. Food and Drug Administration (FDA) acceptance of the company's supplemental new drug application for AYVAKIT (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM).
Moreover, many clinical trials are going on for the development of novel therapeutics that show better results in the management of mastocytosis. The regulatory approvals increase the trust in patients about the development and adoption of novel therapeutics.
For instance, on September 11, 2023, Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, released the Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM). HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frameshifting and already has an Orphan Drug Designation from the FDA.
In addition, ongoing research and development efforts lead to the discovery of new therapeutics and the development of innovative drugs. As the understanding of mastocytosis at the molecular and cellular levels improves, novel therapeutics with targeted mechanisms of action may be identified and developed.
Further, the increasing prevalence of mastocytosis, rising FDA approvals, increasing clinical trials, increasing awareness about mastocytosis and available treatments and advancements in developing novel drugs and advanced therapies are expected to drive the market over the forecast period.
Restraints
Factors such as complications associated with the various drugs used in the mastocytosis treatment, adverse effects associated with the topical corticosteroids, the high cost of the treatment of mastocytosis, availability of limited approved treatments and lack of appropriate treatment are expected to hamper the market.
Segment Analysis
The global mastocytosis treatment market is segmented based on disease type, treatment type, sales channel and region.
The mast-cell stabilizers segment accounted for approximately 45.2% of the mastocytosis treatment market share
The mast-cell stabilizers segment is expected to hold the largest market share over the forecast period. Usually, there is no cure for mastocytosis, but various types of drugs, therapies and various treatment options are used to minimize the symptoms of mastocytosis. The mast cell stabilizers are the most commonly used for the treatment of mastocytosis. The mast cell stabilizers such as cromolyn sodium and ketotifen are most commonly used.
For instance, on January 5, 2022, Ritedose, a pharmaceutical manufacturer, launched a new single-unit dose generic product, Cromolyn Sodium Oral Solution, 100 mg/5 ml. The oral solution is the first of a new product line for Ritedose Pharmaceuticals which has historically offered a portfolio of generic inhalation solutions. Cromolyn Sodium is a mast cell stabilizer, primarily used to treat the symptoms of mastocytosis.
Moreover, in mastocytosis, the mast cells are overly sensitive and can release excessive amounts of mediators like histamine, prostaglandins, and leukotrienes. Mast cell stabilizers, such as cromolyn sodium and nedocromil, work by stabilizing the membranes of mast cells, preventing them from releasing these inflammatory substances.
Further, mast cell activation leads to various symptoms, including itching, flushing, abdominal pain, and in severe cases, anaphylaxis. By inhibiting the release of mast cell mediators, mast cell stabilizers help reduce the intensity and frequency of these symptoms, improving the overall quality of life for individuals with mastocytosis and their wide adoption also increases the demand for mast cell stabilizers.
Geographical Analysis
North America accounted for approximately 39.1% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare facilities. North America especially the United States is well-known for its strong presence of major players such as pharmaceutical companies and medical device companies developing mastocytosis treatment products. The presence of major players actively perform in clinical trials and research activities to develop novel and advanced therapeutics for the treatment of mastocytosis.
Furthermore, the region is also known for the presence of advanced healthcare infrastructure such as hospitals, specialty clinics, research and academic centers and others, which provides advanced healthcare facilities for patients in the treatment of mastocytosis by using advanced therapies for better patient outcomes. The region’s advanced healthcare facilities help to early prevention of the condition with minimal risks.
Competitive Landscape
The major global players in the mastocytosis treatment market include Novartis AG, Mylan N.V., Apotex Inc., Blueprint Medicines Corporation, CStone Pharmaceuticals, Viatris Inc., Cigna HealthCare, Ralington Pharma, Enzo Life Sciences, Inc., Genentech USA, Inc. and among others.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global mastocytosis treatment market. The pandemic affected the initiation and conduct of clinical trials. Research efforts, including those aimed at developing new treatments for mastocytosis, are temporarily disrupted due to the redirected focus on the COVID-19 pandemic. The pandemic also disrupted the supply chain of these treatment medications globally.
Market Segmentation
By Disease Type
• Cutaneous Mastocytosis
o Maculopapular Cutaneous Mastocytosis (Urticaria Pigmentosa)
o Diffuse Cutaneous Mastocytosis
o Mastocytoma of Skin (Solitary Mastocytoma)
o Telangiectasia Macularis Eruptiva Perstans
• Systemic Mastocytosis
o Indolent Systemic Mastocytosis
o Smoldering Systemic Mastocytosis
o Systemic Mastocytosis with Another Blood or Bone Marrow Disorder
o Aggressive Systemic Mastocytosis
o Mast Cell Leukemia
By Treatment Type
• Antihistamines
o H1 Antihistamines
o H2 Antihistamines
• Leukotriene Modifiers
• Mast Cell Stabilizers
o Cromolyn Sodium
o Ketotifen
• Topical Corticosteroids
• Oral Steroids
• Bisphosphonates
• Injectable Epinephrine
• Chemotherapy
o Cladribine
o Imatinib
o Others
• Allogeneic Hematopoietic Stem Cell Transplant (Bone Marrow Transplant)
• Osteoporosis Therapy
• Others
By Sales Channel
• Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• End-User
o Hospitals
o Specialty Clinics
o Dermatology Clinics
o Research and Academic Centers
o Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Why Purchase the Report?
• To visualize the global mastocytosis treatment market segmentation based on disease type, treatment type, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of mastocytosis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global mastocytosis treatment market report would provide approximately 61 tables, 63 figures, and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Treatment Type
3.3. Snippet by Sales Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Adoption for Novel Therapeutics
4.1.2. Restraints
4.1.2.1. Complications Associated with the Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. Patent Analysis
5.8. Volume Analysis
5.9. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Cutaneous Mastocytosis*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Maculopapular Cutaneous Mastocytosis (Urticaria Pigmentosa)
7.2.4. Diffuse Cutaneous Mastocytosis
7.2.5. Mastocytoma of Skin (Solitary Mastocytoma)
7.2.6. Telangiectasia Macularis Eruptiva Perstans
7.3. Systemic Mastocytosis
7.3.1. Indolent Systemic Mastocytosis
7.3.2. Smoldering Systemic Mastocytosis
7.3.3. Systemic Mastocytosis with Another Blood or Bone Marrow Disorder
7.3.4. Aggressive Systemic Mastocytosis
7.3.5. Mast Cell Leukemia
8. By Treatment Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Antihistamines*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. H1 Antihistamines
8.2.4. H2 Antihistamines
8.3. Leukotriene Modifiers
8.4. Mast Cell Stabilizers
8.4.1. Cromolyn Sodium
8.4.2. Ketotifen
8.5. Topical Corticosteroids
8.6. Oral Steroids
8.7. Bisphosphonates
8.8. Injectable Epinephrine
8.9. Chemotherapy
8.9.1. Cladribine
8.9.2. Imatinib
8.9.3. Others
8.10. Allogeneic Hematopoietic Stem Cell Transplant (Bone Marrow Transplant)
8.11. Osteoporosis Therapy
8.12. Others
9. By Sales Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
9.1.2. Market Attractiveness Index, By Sales Channel
9.2. Distribution Channel*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Hospital Pharmacies
9.2.4. Retail Pharmacies
9.2.5. Online Pharmacies
9.3. End-User
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Dermatology Clinics
9.3.4. Research and Academic Centers
9.3.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Novartis AG*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Mylan N.V.
12.3. Apotex Inc.
12.4. Blueprint Medicines Corporation
12.5. CStone Pharmaceuticals
12.6. Viatris Inc.
12.7. Cigna HealthCare
12.8. Ralington Pharma
12.9. Enzo Life Sciences, Inc.
12.10. Genentech USA, Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Novartis AG, 4.	Key Developments, Mylan N.V., Apotex Inc., Blueprint Medicines Corporation, CStone Pharmaceuticals, Viatris Inc., Cigna HealthCare, Ralington Pharma, Enzo Life Sciences, Inc., Genentech USA, Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Mastocytosis Treatment Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Mastocytosis Treatment Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Mastocytosis Treatment Market Value, By Sales Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Mastocytosis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Mastocytosis Treatment Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Mastocytosis Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 7 Global Mastocytosis Treatment Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Mastocytosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 9 Global Mastocytosis Treatment Market Value, By Sales Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Mastocytosis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 11 Global Mastocytosis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Mastocytosis Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Mastocytosis Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 14 North America Mastocytosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 15 North America Mastocytosis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 16 North America Mastocytosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Mastocytosis Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 18 South America Mastocytosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 19 South America Mastocytosis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 20 South America Mastocytosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Mastocytosis Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 22 Europe Mastocytosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 23 Europe Mastocytosis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 24 Europe Mastocytosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Mastocytosis Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Mastocytosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Mastocytosis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Mastocytosis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Mastocytosis Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Mastocytosis Treatment Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Mastocytosis Treatment Market Value, By Sales Channel, 2021-2030 (US$ Million)

Table 32 Novartis AG: Overview

Table 33 Novartis AG: Product Portfolio

Table 34 Novartis AG: Key Developments

Table 35 Mylan N.V.: Overview

Table 36 Mylan N.V.: Product Portfolio

Table 37 Mylan N.V.: Key Developments

Table 38 Apotex Inc.: Overview

Table 39 Apotex Inc.: Product Portfolio

Table 40 Apotex Inc.: Key Developments

Table 41 Blueprint Medicines Corporation: Overview

Table 42 Blueprint Medicines Corporation: Product Portfolio

Table 43 Blueprint Medicines Corporation: Key Developments

Table 44 CStone Pharmaceuticals: Overview

Table 45 CStone Pharmaceuticals: Product Portfolio

Table 46 CStone Pharmaceuticals: Key Developments

Table 47 Viatris Inc.: Overview

Table 48 Viatris Inc.: Product Portfolio

Table 49 Viatris Inc.: Key Developments

Table 50 Cigna HealthCare: Overview

Table 51 Cigna HealthCare: Product Portfolio

Table 52 Cigna HealthCare: Key Developments

Table 53 Ralington Pharma: Overview

Table 54 Ralington Pharma: Product Portfolio

Table 55 Ralington Pharma: Key Developments

Table 56 Enzo Life Sciences, Inc.: Overview

Table 57 Enzo Life Sciences, Inc.: Product Portfolio

Table 58 Enzo Life Sciences, Inc.: Key Developments

Table 59 Genentech USA, Inc.: Overview

Table 60 Genentech USA, Inc.: Product Portfolio

Table 61 Genentech USA, Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Mastocytosis Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 3 Global Mastocytosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 4 Global Mastocytosis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 5 Global Mastocytosis Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Mastocytosis Treatment Market Y-o-Y Growth, By Disease Type, 2022-2030 (%)

Figure 7 Cutaneous Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Systemic Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Global Mastocytosis Treatment Market Y-o-Y Growth, By Treatment Type, 2022-2030 (%)

Figure 10 Antihistamines Treatment Type in Global Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Leukotriene Modifiers Treatment Type in Global Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Mast Cell Stabilizers Treatment Type in Global Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 13 Topical Corticosteroids Treatment Type in Global Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Oral Steroids Treatment Type in Global Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Bisphosphonates Treatment Type in Global Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Injectable Epinephrine Treatment Type in Global Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 17 Chemotherapy Treatment Type in Global Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Allogeneic Hematopoietic Stem Cell Transplant (Bone Marrow Transplant) Treatment Type in Global Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Osteoporosis Therapy Treatment Type in Global Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Others Treatment Type in Global Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 21 Global Mastocytosis Treatment Market Y-o-Y Growth, By Sales Channel, 2022-2030 (%)

Figure 22 Distribution Channel Sales Channel in Global Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 End-User Sales Channel in Global Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 Global Mastocytosis Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 25 North America Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 Asia-Pacific Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 Europe Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 28 South America Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 29 Middle East and Africa Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 30 North America Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 31 North America Mastocytosis Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 32 North America Mastocytosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 33 North America Mastocytosis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 34 North America Mastocytosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 35 South America Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 36 South America Mastocytosis Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 37 South America Mastocytosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 38 South America Mastocytosis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 39 South America Mastocytosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 40 Europe Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 41 Europe Mastocytosis Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 42 Europe Mastocytosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 43 Europe Mastocytosis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 44 Europe Mastocytosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 45 Asia-Pacific Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 46 Asia-Pacific Mastocytosis Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 47 Asia-Pacific Mastocytosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 48 Asia-Pacific Mastocytosis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 49 Asia-Pacific Mastocytosis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 50 Middle East & Africa Mastocytosis Treatment Market Value, 2021-2030 (US$ Million)

Figure 51 Middle East & Africa Mastocytosis Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 52 Middle East & Africa Mastocytosis Treatment Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 53 Middle East & Africa Mastocytosis Treatment Market Share, By Sales Channel, 2022 & 2030 (%)

Figure 54 Novartis AG: Financials

Figure 55 Mylan N.V.: Financials

Figure 56 Apotex Inc.: Financials

Figure 57 Blueprint Medicines Corporation: Financials

Figure 58 CStone Pharmaceuticals: Financials

Figure 59 Viatris Inc.: Financials

Figure 60 Cigna HealthCare: Financials

Figure 61 Ralington Pharma: Financials

Figure 62 Enzo Life Sciences, Inc.: Financials

Figure 63 Genentech USA, Inc.: Financials

세계 비만세포증 치료 시장 – 2023-2030

Global Mastocytosis Treatment Market - 2023-2030